Cumulative Metformin Use and Its Impact on Survival in Gastric Cancer Patients After Gastrectomy

Lee, Choong-kun MD^*; Jung, Minkyu MD^*; Jung, Inkyung PhD^†; Heo, Su Jin MD^*; Jeong, Yong Hyu MD^‡; An, Ji Yeong MD, PhD^§; Kim, Hyoung-Il MD^§; Cheong, Jae-Ho MD, PhD^§; Hyung, Woo Jin MD, PhD^§; Noh, Sung Hoon MD, PhD^§; Kim, Hyo Song MD^*; Rha, Sun Young MD, PhD^*; Chung, Hyun Cheol MD, PhD^*

Annals of Surgery: January 2016 - Volume 263 - Issue 1 - p 96–102

doi: 10.1097/SLA.0000000000001086

Original Articles

Objective: The aim of this study was to evaluate the association between metformin and survival of gastric cancer (GC) patients.

Background: Metformin has recently received attention as a potential anticancer treatment. However, no study has shown the survival benefit of metformin for GC patients.

Methods: A total of 1974 GC patients who underwent curative gastrectomy were compared for survival according to groups; 132 diabetic patients treated with metformin, 194 diabetic patients without metformin, and 1648 non-diabetic patients.

Conclusions: The increased cumulative duration of metformin use decreased the recurrence, all-cause mortality, and cancer-specific mortality rates among GC patients with diabetes who underwent gastrectomy.

http://journals.lww.com/annalsofsurgery/Abstract/2016/01000/Cumulative_Metformin_Use_and_Its_Impact_on.16.aspx